Cambridge, MA - June 13, 2013 - Verastem, Inc., focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that VS-6063 has received orphan medicinal product designation from the European Commission for use in mesothelioma.
http://www.drugs.com/clinical_trials/verastem-receives-orphan-designation-eu-vs-6063-mesothelioma-15730.html?
http://www.drugs.com/clinical_trials/verastem-receives-orphan-designation-eu-vs-6063-mesothelioma-15730.html?
No comments:
Post a Comment